Newborn Screening: Ontario’s Expanded Screening Program - PowerPoint PPT Presentation

1 / 67
About This Presentation
Title:

Newborn Screening: Ontario’s Expanded Screening Program

Description:

Newborn Screening: Ontario s Expanded Screening Program Prepared by: June C. Carroll, MD, CCFP, FCFP Sydney G. Frankfort Chair in Family Medicine – PowerPoint PPT presentation

Number of Views:493
Avg rating:3.0/5.0
Slides: 68
Provided by: effectivep8
Category:

less

Transcript and Presenter's Notes

Title: Newborn Screening: Ontario’s Expanded Screening Program


1
Newborn Screening Ontarios Expanded Screening
Program
Prepared by June C. Carroll, MD, CCFP,
FCFP Sydney G. Frankfort Chair in Family
Medicine Associate Professor, Department of
Family Medicine Mount Sinai Hospital,
University of Toronto Andrea L. Rideout, MS,
CCGC, CGC Project Manager / Genetic Counsellor
The Genetics Education Project Funded
by Ontario Womens Health Council Version
August 2007
2
Acknowledgments
  • Reviewers
  • Members of The Genetics Education Project
  • Ontario Newborn Screening Program Dr. Michael
    Geraghty, Mireille Cloutier MSC., Christina
    Honeywell MSc., Sari Zelenietz MSc.
  • Funded by
  • Ontario Womens Health Council as part of its
    funding to The Genetics Education Project
  • Health care providers must use their own
    clinical judgment in addition to the information
    presented herein. The authors assume no
    responsibility or liability resulting from the
    use of information in this presentation.

3
Newborn Screening Whats new?
  • Previously
  • PKU, congenital hypothyroidism, hearing loss
  • Beginning April 2006
  • Progressive expansion to 29 disorders by the end
    of 2008
  • NBS includes hearing screening but, the focus of
    this module will be on metabolic, endocrine and
    hematologic conditions

4
Expanded NBS 29 conditions
  • 20 inborn errors of metabolism
  • 9 organic acid disorders
  • 5 fatty acid oxidation disorders
  • 6 amino acid disorders
  • 3 hemoglobinopathies
  • Sickle cell and related disorders
  • 2 endocrine disorders
  • 3 other metabolic disorders
  • 1 hearing loss

5
Benefits of NBS
  • Identification
  • Early intervention
  • Reduced morbidity and mortality
  • Family planning

6
Risks of NBS
  • Parental anxiety (false positives)
  • Missed diagnosis (false negatives)
  • The right not to know
  • Unanticipated outcomes
  • Labelling diagnosis of benign conditions

7
Publics attitude to NBS
  • Study of 200 Australian new mothers
  • Quinlivan 2006 J Pscyhosomatic Ob/Gyn
  • Supported NBS where outcomes used to prevent or
    reduce severity of disease (85)
  • Less support if screening used for future family
    planning (65)
  • Parental consent should be mandatory (86)
  • Majority concerned re discrimination, difficulty
    getting insurance/employment for those with
    genetic condition
  • 1/3 had similar concerns for carriers

8
Why Changes to NBS now?
  • Reagent for PKU test unavailable
  • Tandem Mass Spectrometry more efficient
  • 2 infants diagnosed post-mortem with MCAD
  • Ombudsmans report 2005
  • Consumer lobbying
  • Geneticist lobbying
  • Political will

9
NBS Whats NOT changing?
  • Heel prick method for sample collection

NBS Whats changing?
  • New screening card
  • Location Childrens Hospital of Eastern Ontario
  • Transportation sample cards are sent via Canada
    Post courier service to Ontario NBS Program

10
Timing of Testing
  • Acceptable samples
  • between 1 day (24 hours) and 7 days after birth
  • Best time for sample
  • between 2 days (48 hours) and 3 days (72 hours)
    after birth
  • If tested before 1 day (24 hours) of age, REPEAT
    the test within 5 days
  • If the baby is gt5 days, screening is still
    available
  • Contact Ontario NBS program for details
  • Repeat sample within 5 days has been the
    Ontario standard of care since 2001

11
Special Considerations
  • Prematurity or illness
  • If lt37 weeks - collect specimen at 5-7 days old
  • Indicate this on NBS card
  • i.e. associated with false ve congenital
    hypothyroidism screens
  • Total Parenteral Nutrition (TPN)
  • Certain amino acids and organic acids will be
    elevated
  • Indicate this on NBS card
  • Transfusion
  • Disorders may be missed
  • Ideally complete card before transfusion

12
The Heel Test
13
What makes a good spot?
14
NBS Whats New?
  • Location
  • Childrens Hospital of Eastern Ontario (CHEO)
  • Tandem Mass Spectrometry
  • Allows to screen for multiple conditions
    concurrently
  • Same cost to screen for one condition as multiple
  • Increased sensitivity and specificity
  • Screening for some metabolites can give
    information about several diseases
  • Educational materials
  • MOH CHEO have developed materials for the
    public and healthcare providers
  • Parents will ask you about NBS

15
NBS Report
  • Cystic fibrosis
  • 2008

16
Screen Positive Results
  • Screen positive means
  • Further testing is required to confirm the
    diagnosis
  • Does NOT mean that the infant is affected
  • NBS laboratory will immediately notify regional
    treatment centre
  • Regional treatment centre will notify the
    infants healthcare provider and parents and
    arrange confirmatory testing
  • If diagnosis is confirmed, regional treatment
    centre will provide management counselling
    follow up
  • Report will be mailed to referring hospital and
    HCP, provided that correct information is
    completed on the screening card.

17
Results of Expanded NBS by MS/MSSchulze et al.
Pediatrics 2003
  • 250,000 neonates screened for 23 IEM
  • 106 newborns with confirmed metabolic disorder
  • 70 required treatment
  • Overall prevalence of metabolic disorder 1/2400
  • 825 false positives (0.33 false positive rate)
  • Overall specificity 99.67 (PPV 11.3)
  • Overall sensitivity 100 for classic forms of
    disorders
  • 92.6 for variants
  • 61 /106 were judged to have benefited from
    screening and treatment
  • 58 of true positives
  • 1/4100 newborns

18
Results
  • Results will go to
  • Submitting health care professional /hospital
  • Infants health care professional if this
    information is completed on the screening card

19
Expanded NBS 29 conditions
  • 20 inborn errors of metabolism
  • 9 organic acid disorders
  • 5 fatty acid oxidation disorders
  • 6 amino acid disorders
  • 3 hemoglobinopathies
  • Sickle cell and related disorders
  • 2 endocrine disorders
  • 3 other metabolic disorders
  • 1 hearing loss

20
Inborn errors of metabolism
  • Rare
  • Usually autosomal recessive inheritance
  • consanguinity is more common
  • Symptoms secondary to a problem in the metabolic
    pathway
  • Usually not significant dysmorphism
  • Early recognition and intervention can be
    lifesaving

21
Frequency of Inborn Errors of Metabolism using
MS/MS Tandem Mass Spectrometry
  • Amino Acid Disorders 1/5,100
  • Organic Acid Disorders 1/20,000
  • Fatty Acid Oxidation Defects 1/12,500
  • IEM combined frequency 1/4,000
  • All NBS IEM, CF, CAH, 1/1,500
  • biotinidase, galactosemia

22
Organic Acid Disorders
  • Isovaleric acidemia (IVA)
  • Glutaric acidemia type 1 (GA1)
  • Hydrodroxymethylglutaric acidemia (HMG)
  • Multiple carboxylase deficiency (MCD)
  • Methylmalonic acidemia (MUT)
  • Methylmalonic acidemia (Cbl A, B)
  • 3-methylcrotonyl glycinuria (3MCG)
  • Propionic acidemia (PROP)
  • ?-ketothiolase deficiency (BKT)

23
Organic Acid Disorders
  • What are organic acid disorders?
  • Body cannot metabolize certain amino acids and
    fats
  • Accumulation of organic acids in blood and urine
  • Serious potentially preventable effects on health
    and development, including death
  • Symptoms
  • acute encephalopathy, vomiting, metabolic
    acidosis, ketosis, hyperammonemia, hypoglycemia,
    coma
  • dehydration, failure to thrive, hypotonia, GDD
  • sepsis, death
  • Treatment
  • Low protein diet / restrict amino acids,
  • Supplements carnitine, biotin, riboflavin,
    glycine
  • Avoid fasting

24
Fatty Acid Oxidation Disorders
  • Medium-chain acyl-CoA dehydrogenase (MCAD)
    deficiency
  • Very long-chain acyl-CoA dehydrogenase deficiency
    (VLCAD)
  • Long-chain L-3-OH acyl-CoA dehydrogenase
    deficiency (LCHAD)
  • Trifunctional protein deficiency (TFP)
  • catalyzes 3 steps in mitochondrial beta-oxidation
    of fatty acids
  • Carnitine uptake defect (CUD)

25
Disorders of Fatty Acid Oxidation
  • What are disorders of fatty acid oxidation?
  • Breakdown of fatty acids in mitochondria is
    essential part of bodys ability to produce
    energy
  • Disorder inability to break down fatty acids
  • Symptoms
  • Decompensate with any catabolic stress
  • fever, fasting, intercurrent illness
  • Hypoketotic hypoglycemia, liver, muscle, heart
    disease
  • Lethargy, seizures, coma, sudden death (SIDS)
  • Treatment
  • Avoid fasting
  • Frequent feeding
  • IV glucose when ill to prevent hypoglycemia

26
Amino Acid Disorders
  • Phenylketonuria (PKU)
  • Maple syrup urine disease (MSUD)
  • Tyrosinemia type 1 (TYR 1)
  • Common in French Canadians
  • Homocystinuria (HCY)
  • Citrullinemia (CIT)
  • Argininosuccinic aciduria (ASA)

27
Amino Acid Disorders
  • What are Amino acid disorders?
  • Occur when the body cannot either metabolize or
    produce certain amino acids
  • Results in toxic accumulation of substances
  • Serious potentially preventable effects on health
    and development including death
  • Symptoms -example PKU
  • Hyperphenylalaninemia (neurotoxic)
  • Microcephaly, epilepsy, MR, behaviour problems
  • Treatment
  • Diet reduce phenylalanine, low protein,
    supplement cofactors or essential amino acids
  • Avoid fasting

28
Endocrine Disorders CH
  • Congenital Hypothyroidism (CH)
  • What is CH?
  • inadequate thyroid hormone production
  • Anatomic defect in gland, IEM, iodine deficiency
  • Symptoms
  • MR, ? growth bone maturation, neurologic
    problems spasticity, gait abn, dysarthria,
    autistic behaviour
  • Treatment
  • Thyroid hormone replacement
  • Diagnosis made before 13 days to prevent symptoms

29
Endocrine Disorders CAH
  • Congenital Adrenal Hyperplasia (CAH)
  • What is CAH?
  • Impaired synthesis of cortisol by the adrenal
    cortex leads to ??? androgen biosynthesis
  • Inability to maintain adequate energy blood
    glucose level to meet stress of injury illness
  • Symptoms
  • Virilization (? ambiguous genitalia), precocious
    puberty, infertility, short stature
  • Renal salt wasting leads to FTT, vomiting,
    dehydration, hypotension, hyponatremia,
    hyperkalemia
  • Treatment
  • Glucocorticoid replacement therapy

30
Hemoglobinopathies
  • Sickle cell disease (Hb SS)
  • Hemoglobin SC disease
  • Sickle-ß thalassemia (Hb S/ß-thal)
  • Other hemoglobin variants may be picked up as
    variants

31
Sickle Cell Disease
  • What is sickle cell disease? (Hb SS)
  • Change in the shape of the betaglobin component
    of the hemoglobin molecule that interferes with
    hemoglobins ability to carry oxygen
  • Symptoms
  • Painful vaso-occlusive crises, hemolytic anemia,
    frequent infections, tissue ischemia, chronic
    organ dysfunction
  • Diagnosis
  • Quantitative hemoglobin electrophoresis
  • Do not rely on solubility testing methods
    (Sickledex etc)
  • Treatment
  • Prophylactic penicillin (84 reduction in
    infection)
  • Vaccinations (pneumococcal, influenza)

32
Other Hemoglobinopathies
  • Hemoglobin C disease (Hb-CC)
  • benign hemoglobinopathy
  • mild hemolytic anemia, retinopathy dental
    infarctions, gallstones, splenomegaly, joint pain
  • Sickle cell and C trait (carriers) (Hb AS, Hb AC)
  • gt 50 normal hemoglobin generally asymptomatic
    no clinical symptoms
  • Other hemoglobin variants
  • Autosomal recessive inheritance

33
Other DisordersBiotinidase deficiency
  • What is biotinidase deficiency?
  • Biotinidase is responsible for recycling biotin
    a cofactor for 4 dependant carboxylases
  • Symptoms
  • Metabolic ketoacidosis, organic aciduria, mild
    hyperammonemia
  • Seizures, hypotonia, ataxia, developmental delay,
    vision problems, hearing loss, cutaneous
    abnormalities
  • Treatment
  • 5-10mg of oral biotin per day, long term
    treatment prevents all symptoms

34
Other Disorders Galactosemia
  • What is galactosemia?
  • Lactose is main sugar in breast milk infant
    formulas
  • Metabolized into glucose and galactose in the
    intestine
  • Unable to break down galactose
  • Symptoms
  • Feeding problems, FTT, bleeding, infection, liver
    failure, cataracts, MR
  • Treatment
  • Lactose-galactose-restricted diet
  • must be started in first 10 days of life to
    prevent symptoms
  • Even with treatment - ? developmental delay,
    speech problems, abn motor function, premature
    ovarian failure

35
Other Disorders Cystic fibrosis
  • What is cystic fibrosis?
  • Due to mutations in the CFTR gene which is
    responsible for chloride regulation and other
    transport pathways.
  • Symptoms
  • Chronic sinopulmonary disease
  • Gastrointestinal/nutritional abnormalities
  • Azoospermia (males)
  • Salt loss syndrome
  • Shortened life span but improving with
    treatment
  • Treatment
  • Pulmonary oral, inhaled, or IV antibiotics,
    bronchodilators, anti-inflammatory agents,
    mucolytic agents, chest physiotherapy
  • Gastrointestinal Nutritional therapy special
    formulas for weight gain via improved intestinal
    absorption, and additional fat-soluble vitamins
    zinc to prevent deficiencies

36
Cases
37
Case 1
  • Carmen and George bring Amy into your office for
    1 week visit
  • Healthy 1 week old
  • Parents worried re risk of SIDS
  • First daughter died of SIDS 5 years earlier
  • Carmens cousin died of SIDS at 18 months

38
Case 1 Amy 5 days old
  • You receive a call that Amy has screened positive
    for MCAD deficiency
  • Medium chain acyl-CoA dehydrogenase deficiency
  • You ask Carmen and George to bring her in that
    day
  • Healthy 5 day old
  • Parents worried about risk of SIDS
  • First daughter died of SIDS 5 years earlier
  • Carmens cousin died of SIDS at 13 months

39
Case 1
British / French
Irish / German
72 AW
79 Prost Ca Dx 74
49 Accident
65 AW
MI died 69
25 AW
29 AW
37 Schizophrenic
32 Carmen AW
39 AW
35 George AW
SIDS 13 months
1 wk Amy A W
7 5 AW
AW
SIDS 8 months
40
Case 1
  • Amys expanded newborn screening report is the
    following
  • Screen positive for medium chain acyl-CoA
    deficiency

41
MCAD (medium chain acyl-CoA deficiency)
  • Incidence
  • 1 in 4,900 1 in 17,000
  • most prevalent in North Europeans
  • Inheritance
  • Autosomal recessive (Gene ACADM)
  • Enzyme
  • Medium-chain acyl-coenzyme A dehydrogenase
  • Function
  • Mitochrondrial fatty acid ß-oxidation
  • Energy source once hepatic glycogen stores become
    depleted
  • Important during prolonged fasting

42
MCAD Symptoms
  • Usually presents at 3 to 24 months
  • Triggered by fever, illness, or fasting
  • Symptoms
  • Hypoglycemia, vomiting
  • Lethargy ? coma ? death
  • Encephalopathy, respiratory arrest, hepatomegaly,
    seizures
  • Long term outcomes developmental behavioural
    disabilities, chronic muscle weakness, seizures,
    cerebral palsy, ADD

43
MCAD a preventable cause of SIDS
  • Sudden death is the first symptom in 25 of MCAD
    cases
  • Early diagnosis and treatment of MCAD can prevent
    sudden death
  • MCAD responsible for 1 of SIDS cases, all FAO
    disorders 4
  • Opdal et al. Pediatrics 2004114506-512

44
MCAD Management
  • Infants require frequent feedings
  • Formulas containing medium chain triglycerides as
    the primary source of fat should be avoided
  • Toddlers 2g/kg of uncooked cornstarch at bedtime
    to ensure sufficient glucose overnight
  • High carbohydrate, low fat diet
  • Carnitine supplementation
  • Avoid fasting, hypoglycemia

45
Case 2
  • Peter and Tina come to your office for a routine
    newborn visit
  • Kechia is a healthy 1 week old newborn
  • Her NBS results show that she is a carrier of
    hemoglobin S - sickle cell trait
  • How would you proceed?

46
Hemoglobin S Carriers
  • Carriers of sickle cell trait (HbAS)
  • no clinical symptoms
  • should they be notified?
  • Benefits
  • Sequential testing and identification of
    carriers/ affected in family
  • Reproductive counselling/prenatal diagnosis
  • Risks
  • Exposure of non-paternity
  • Fear of chronic illness
  • Fear of sickle cell disease in future pregnancies
  • Stigmatization
  • Diminished self esteem
  • Potential discrimination
  • Misdiagnosis

47
Case 2 sequential testing of family members
Barbados
Jamaica
Hb - AA
22 Hb - AS
24 Hb - AS
Hb - AA
Hb - AS
Hb - AA
Hb - AS
Hb - AS
Hb - AA
Hb - AS
P
3months Hb - SS
1 week Hb - AS
Hb - AA
Hb - AA
Hb - AA
Hb - AA
48
Prevalence Hemoglobinopathies
In cis 2 a thal deletions on same chromosome
Source March of Dimes
49
NBS Bottom Line
  • Offer newborn screening
  • Discuss the benefits
  • Discuss how testing is done
  • Discuss timing
  • Repeat sample sometimes required
  • Discuss difference between screening and
    diagnostic test
  • Discuss possible results
  • Answer questions/brochure

50
MOH Educational Materials
  • www.health.gov.on.ca/newbornscreening
  • MOHLTC INFOline at 1-866-532-3161 / TTY
    1-800-387-5559
  • Contact the Ontario Newborn Screening Program at
  • Department of Genetics
  • Childrens Hospital of Eastern Ontario
  • Room 3127, 401 Smyth Road
  • Ottawa, ON K1H 8L1
  • (613) 738-3222
  • Educational materials are available
    free-of-charge and can be ordered through
    www.health.gov.on.ca or by calling 1-877-844-1944

51
Educationhttp//www.health.gov.on.ca
52
  • Disorder Fact Sheets
  • www.health.gov.on.ca/newbornscreening

53
Resources
  • CHEOs Newborn Screening Website
  • http//www.newbornscreening.on.ca/bins/index.asp
  • March of Dimes
  • www.marchofdimes.com
  • Genetests
  • www.genetests.org
  • National Newborn Screening Genetics Resource
    Center
  • genes-r-us.uthscsa.edu
  • Pediatrix US private lab offering NBS
  • www.pediatrix.com

54
The Genetics Education Project Committee
  • June Carroll MD CCFP
  • Judith Allanson MD FRCP FRCP(C) FCCMG FABMG
  • Sean Blaine MD CCFP
  • Mary Jane Esplen PhD RN
  • Sandra Farrell MD FRCPC FCCMG
  • Judy Fiddes
  • Gail Graham MD FRCPC FCCMG
  • Jennifer MacKenzie MD FRCPC FAAP FCCMG
  • Wendy Meschino MD FRCPC FCCMG
  • Fiona Miller PhD
  • Ms. Joanne Miyazaki
  • Andrea Rideout MS CGC CCGC
  • Linda Spooner RN BScN
  • Cheryl Shuman MS CGC
  • Anne Summers MD FCCMG FRCPC
  • Sherry Taylor PhD FCCMG
  • Brenda Wilson BSc MB ChB MSc MRCP(UK) FFPH

55
References
  • Ontario Ministry of Health and Long Term Care,
    News release November 2, 2005 Ontario becomes
    national leader in newborn screening, New
    state-of-the-art testing program means that
    children will have a better start on life
    http//www.health.gov.on.ca/english/media/news_rel
    eases/archives/nr_05/nr_110205.html
  • Ontario Ministry of Health and Long Term Care,
    News release November 23, 2006 McGuinty
    government expands newborn screening, Screening
    for cystic fibrosis brings total number of tests
    to 28. http//www.health.gov.on.ca/english/media/n
    ews_releases/archives/nr_06/nov/nr_112306.html
  • Bellis MA, Hughes K, Hughes S, Aston JR.
    Measuring parent discrepancy and its public
    health consequences. J Epidemiol Community Health
    2005 59 749-754.
  • Quinlivan 2006 J Pscyhosomatic Ob/Gyn
  • Holtzman NA, Faden R, Chwalow AJ, Horn SD. Effect
    of informed parental consent on mothers'
    knowledge of newborn screening. Pediatrics. 1983
    72807-812.

56
References
  • Tymstra T. False positive results in screening
    tests experiences of parents of children
    screened for congenital hypothyroidism. Fam
    Pract. 1986 392-96.
  • Tluczek A, Mischler EH, Bowers B, Peterson NM,
    Morris ME, Farrell PM, Bruns WT, Colby H,
    McCarthy C, Fost N, et al. Psychological impact
    of false-positive results when screening for
    cystic fibrosis. Pediatr Pulmonol Suppl.
    1991729-37.
  • Waisbren SE, Albers S, Amato S, Ampola M,
    Brewster TG, Demmer L, Eaton RB, Greenstein R,
    Korson M, Larson C, Marsden D, Msall M, Naylor
    EW, Pueschel S, Seashore M, Shih VE, Levy HL.
    Effect of expanded newborn screening for
    biochemical genetic disorders on child outcomes
    and parental stress. JAMA. 20032902564-2572.
  • Tluczek A, Koscik RL, Farrell PM, Rock MJ.
    Psychosocial risk associated with newborn
    screening for cystic fibrosis parents'
    experience while awaiting the sweat-test
    appointment. Pediatrics. 20051151692-1703.

57
References
  • Mischler EH, Wilfond BS, Fost N, Laxova A, Reiser
    C, Sauer CM, Makholm LM, Shen G, Feenan L,
    McCarthy C, Farrell PM. Cystic fibrosis newborn
    screening impact on reproductive behavior and
    implications for genetic counseling. Pediatrics.
    1998 10244-52.
  • Dudding T, Wilcken B, Burgess B, Hambly J, Turner
    G. Reproductive decisions after neonatal
    screening identifies cystic fibrosis. Arch Dis
    Child Fetal Neonatal Ed. 2000 82F124-127.
  • Martin, A. Ontario Ombudsman Report The Right to
    be impatient. September 2005.
  • Ontario Ministry of Health and Long Term Care,
    Newborn Screening website http//www.health.gov.o
    n.ca/english/providers/program/child/screening/scr
    een_sum.html www.health.gov.on.ca/english/provider
    s/program/child/screening/screen_sum.html
  • NCCLS (National Committee for Clinical Laboratory
    Standards now known as CLSI Clinical Laboratory
    Standards Institute) LAR-A3 Blood collection on
    filter paper for neonatal screening programs
    approved standard, third edition.

58
References
  • Simple Spot Check 04/03/02 Lit. 718 produced
    by Schleicher Schuell BioScience Inc. 10
    Optical Ave, Keene NH 03431 USA. Scheicher
    Schuell BioScience GmbH P.O. Box 1160, D-37582
    Dassel, Germany.
  • Waston MS, Mann MY, Lloyd-Puryear MA, Rinaldo P,
    Howell RR. Executive summary Newborn screening
    panel and system. Genet Med 2006 8 (5,
    supplement) 1s-11s.
  • Schulze A, Lindner M, Kohlmuller D, Olgemoller K,
    Mayatepek E, Hoffmann GF. Expanded newborn
    screening for inborn errors of metabolism by
    electrospray ionization-tandem mass spectrometry
    Results, outcome and implications. Pediatrics
    2003 1111399-1406.
  • Applegarth Da, Toone JR, Lowry RB. Incvidence of
    inborn errors of metabolism in British Columbia,
    1969 1996. Pediatrics 2000 105e10-e16.
  • Frazier DM, Millington DS, McCandless SE, Keoberl
    DD, Weavil Sd, Chaing SH, Muenzer J. The tandem
    mass spectrometry newborn screening experience in
    North Carolina 1997-2005. J Inhert Metab Dis
    2006 2976-85.
  • Marsden D, Larson C, Levy Hl. Newborn screening
    for metabolic disorders. J Pediatr 2006
    148577-584.

59
References
  • Seashore MA. Genetest Reviews The organic
    acidemias An overview. Last updated 27 december
    2006. www.genetests.org.
  • Ogier de Baulny HO, Saudubray JM. Branched-chain
    organic acidurias. Semin Neonatol. 2002 765-74.
  • Venditti CP. Genetests Reviews Methylmalonic
    Acidemia. Last updated 18 January 2007.
    www.genetests.org.
  • Korman SH. Inborn errors of isoleucine
    degradation A review. Mol Genet Metab. 1006
    89289-299.
  • Gibson KM, Breuer J, Kiaser K, Nylan WL, McCoy
    EE, Ferreira P, Greene CL, Blitzer MG, Shapira
    E, Reverte F, Conde C, Bagnell P, Cole DEC.
    3-hydroy-3-methylglutaryl-coenzyme A lyase
    deficiency Report of five new patients. J Inhert
    Metab Dis 1988 1176-87.
  • Roth KS. Holocarboxylase Deficiency. Last updated
    22 September 2005. http//www.emedicine.com/ped/to
    pic1020.htm

60
References
  • Angelini C, Federico A, Reichmann H, Lombes,
    Chinnery P, Turnbull D. Task force guidelines
    handbook EFNS guidelines on diagnosis and
    management of fatty acid mitochondrial disorders.
    Eur J Neurol. 2006 13923-929.
  • Saudubray JM, Martin D, deLonlay P, Touati G,
    Poggi-Travert F, bonnet D, Jouvet P, Boutron M,
    Slama A, Vianey-saban C, Bonnefont JP, Rabier,
    Kamoun P, Brivet M. Recognition and management of
    fatty acid oxidation defects A series of 107
    patients. J Inherit Metabo Dis. 1999 22488-502.
  • Hellekson KL National Institutes of Health. Am
    Fam Physician. 2001 631430 1432.
  • National Institutes of Health Consensus
    Development Panel. National institutes of Health
    consensus development conference statement
    Phenylketonuria screening and management, October
    16-18 2000. Pediatrics 2001 108 972-982.
  • Mitchell JJ, Scriver CR. Genetests Reviews
    Phenylalanine hydroxylase deficiency. Last
    updated 19 July 2005. www.genetests.org.
  • Morton DH, Strauss KA, Robinson DL, Puffenberger
    EG, Kelley RI. Diagnosis and treatment of maple
    syrup urine disease A study of 36 patients.
    Pediatrics 2002 109999-1008.

61
References
  • Le Roux C, Murphy E, Liblurn M. The longest
    surviving patient with classical maple syrup
    urine disease. J Inherit Metab Dis 2006
    29190-194.
  • Strauss KA, Puffenberger EG, Morton DH. Genetests
    Reviews Maple Syrup Urine Disease. Last updated
    30 January 2006. www.genetests.org.
  • Scott CR. The genetic tyrosinemias. Am J Med
    Genet Part C Semin Med Genet 2006 142C121-126.
  • Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia a
    review. Pediatr Dev Pathol. 2001 4212-221.
  • Sniderman King L, Trahms C Scott R. Genetests
    Reviews Tyrosinemia Type I. Last updated 24 July
    2006. www.genetests.org.
  • Walter JH, Wraith JE, White FJ, Bridge C, Till J.
    Strategies for the treatment of cystathionine
    ß-synthase deficiency the experience of the
    Wilink Biochemical Genetics Unit over the past 30
    years. Eur J Pediatr. 1998 157(Suppl 2)s71-s76.

62
References
  • De Franchis R, Sperendeo MP, Sebastio G, Andria
    G. The Italian Study group on Homocystinuria.
    Clinical aspects of the cynstathionine ß-synthase
    deficiency how wide is the clinical spectrum?
    Eur J Pediatr. 1998 157(Suppl 2)s67-s70.
  • Picker JD. Levy HL. Genetests Reviews
    Homocystinuria Caused by Cystathionine
    Beta-Synthase Deficiency. Last updated 29 March
    2006. www.genetests.org.
  • Summar M, Tuchman M. Proceeding of a consensus
    conference for the management of patients with
    urea acid cycle disorders. J Pediatr. 2001
    138(Suppl1)s6-s10.
  • The Urea Cycle Disorders Conference Group.
    Consensus statement from a conference for the
    management of patients with urea cycle disorders.
    J Pediatr. 2001 138(Suppl1)s1-s5.
  • Summar, ML. Genetests Reviews Urea Cycle
    Disorders Overview. Last updated 11 August 2005.
    www.genetests.org.
  • Thoene, JG. Genetests Reviews Citrullinemia Type
    I. Last updated 22 December 2006.
    www.genetests.org

63
References
  • Roth KS. Argininosuccinate Lyase Deficiency. Last
    Updated 7 July 2005. www.emedicine.com - free
    registration is required. If you are already
    registered the direct link is http//www.emedicin
    e.com/ped/topic2745.htm
  • American Academy of Pediatrics Rose SR Section
    on Endocrinology and Committee on Genetics,
    American Thyroid Association Brown RS Public
    Health Committee, Lawson Wilkins Pediatric
    Endocrine Society Foley T, Kaplowitz PB, Kaye
    CI, Sundararajan S, Varma SK. Update of newborn
    screening and therapy for congenital
    hypothyroidism. Pediatrics. 2006
    Jun1172290-2303.
  • Postellon D, Bourgeois MJ, Varma S. eMedicine
    Congenital Hypothyroidism. Last Updated 23
    August 2006 http//www.emedicine.com/ped/topic501
    .htm
  • Merke DP, Bornstein SR. Congenital adrenal
    hyperplasia. Lancet. 2005 365 2125-2136.

64
References
  • New MI, Nimkarn S. GeneTests Reviews Congenital
    Adrenal Hyperplasia, last update 7 September
    2006. http//www.genetests.org.
  • Wethers DL. Sickle cell disease in childhood
    Part II. Diagnosis and treatment of major
    complications and recent advances in treatment.
    Am Fam Physician. 2000 62 1309-1314.
  • Bender MA. GeneTests Reviews Sickle cell
    Disease, last update 7 March 2006.
    http//www.genetests.org
  • Wolf B. Worldwide survey of neonatal screening
    for biotinidase deficiency. J Inherit Metab Dis.
    1991 14923-927.
  • Wolf B. GeneTests Reviews Biotinidase
    Deficiency, last update 2 March 2006.
    http//www.genetests.org.
  • Bosch AM. Classical galatosemia revisited. J
    Inherit. Metab. Dis. 2006 29516-529.

65
References
  • Schweitzer-Krantz S. Early diagnosis of inherited
    metabolic disorders improving outcome the
    controversial issue of galactosemia. Eur J
    Pediatr. 2003 162s50-s503.
  • Elsas LJ. GeneTests Reviews Galactosemia, last
    update 2 May 2005. http//www.genetests.org
  • Moskowitz SM, Gibson RL, Sternen DL, Cutting GR.
    Genetests Reviews CFTR-Related Disorders. Last
    updated 24 August 2005. www.genetests.org.
  • Yankaskas JR, Marshall BC, Sufian B, Simon RH,
    Rodman D. Cystic fibrosis adult care Consensus
    conference report. Chest 2004125s1-s39.
  • Saiman L, Siegel J. Infection control
    recommendations for patients with cystic
    fibrosis Microbiology, important pathogens and
    infection control to prevent patient to patient
    transmission, Cystic fibrosis consensus
    conference on infection control participants. Am
    J Infection Control 2003 31s1-s62.

66
References
  • Cystic Fibrosis Trust Clinical Standards and
    Accreditation Group. Standards of care for
    children and adults with cystic fibrosis in the
    UK. May 2001.
  • Matern D, Rinaldo P. GeneTests Reviews
    Medium-Chain Acyl-Coenzyme A Dehydrogenase
    Deficiency. Last update 3 February 2005.
    http//www.genetests.org
  • Opdal SH, Rognum TO. The sudden infant death
    gene does it exist? Pediatrics 2004
    114506-512.
  • American Academy of Pediatrics, Newborn Screening
    Fact Sheets Kaye CL and the Committee on
    Genetics. Newborn screening fact sheets.
    Pediatrics 2006 118e934-e963.
  • Pass K A, Lane PA, Fernhoff PM, Hinton CF, Panny
    SR, parks JS, Pelias MZ, Rhead WJ, Ross SI,
    Wethers DL, Elsas LJ for CORN. US newborn
    screening system guidelines II Follow-up of
    children, diagnosis, management and evaluation.
    Statement of the councilof regional networks for
    genetic services (CORN). Pediatrics 2000
    137(4)s1-s46.

67
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com